Oncology Search
Oncology Oncology
non-hodgkin's%20lymphoma
NON-HODGKIN'S LYMPHOMA

Non-Hodgkin's lymphoma is a heterogeneous group of lymphoproliferative malignancies.
It is the most common hematologic cancer.
The most common subtypes are the diffuse large B-cell and follicular lymphoma. The subtypes are based on the malignant cell's morphology, genetic features, immunohistological characteristics, and stage of maturation.

Non-Hodgkin's Lymphoma Drug Information

Drug Information

Indication: Metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum-based chemother...

Indication: Adult patients w/ relapsed or refractory mantle cell lymphoma (MCL), previously untreated chronic lymphocytic ...

Indication: Multiple myeloma. Mantle cell lymphoma.

Indication: Multiple myeloma & mantle cell lymphoma (MCL) in patients who have received at least 1 prior therapy.

Indication: Adult patients w/ relapsed or refractory CD30+ Hodgkin lymphoma (HL) following autologous stem cell transplant...

Indication: Regression in neoplastic conditions eg, acute leukaemia, Wilms' tumour, neuroblastoma, soft tissue & bone ...

Indication: Alone or in combination w/ other chemotherapeutic agents for induction of leukaemia remission, particularly fo...

Indication: Induction & maintenance of remission in acute myelocytic leukaemia in adult & childn. Other leukemias ...

Indication: Squamous cell carcinoma of skin, head, neck & oesophagus, larynx, penis & uterine cervix, bronchus. Ch...

Indication: Alone or in combination w/ other chemotherapeutic agents for induction of remission of acute myeloid leukaemia...

1  /  4
1  /  4
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Sintilimab + bevacizumab biosimilar as 1st-line option for advanced HCC?
Pearl Toh, 08 Jan 2021
Combining the anti-PD-1 antibody sintilimab and a bevacizumab biosimilar significantly improves survival compared with the standard treatment of sorafenib in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma (HCC), according to the ORIENT-32 study presented at ESMO Asia 2020.
ESMO calls for cancer patients to be prioritized for COVID-19 vaccination
Dr Margaret Shi, 4 days ago

Cancer patients at are an increased risk of severe coronavirus disease 2019 (COVID-19) and should be positioned at high priority for vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) regardless of age, according to statements issued by the European Society for Medical Oncology (ESMO).